Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the earnings conference call in respect of Unaudited Standalone and Consolidated Financial Results for the Quarter and nine months ended 31st December, 2023 held today i.e. 23rd January, 2024 at 03:30 p.m. (IST) is available on the Company's website at https://www.indoco.com/inv-fin-concall-transcripts.asp. The Earnings Conference Call concluded at 4.25 p.m. (IST) on 23rd January, 2024
23-01-2024
Bigul

Q3FY24 Quarterly Result Announced for Indoco Remedies Ltd.

 Pharmaceuticals firm Indoco Remedies announced Q3FY24 results: Q3FY24 Revenue: Rs 4,484 million (growth of 9.2% compared to Rs 4,106 million in Q3 of the previous year) EBIDTA: Rs 653 million, representing 14.6% of net sales (compared to Rs 617 million or 15.0% of net sales in Q3 of the previous year) Profit After Tax: Rs 282 million (before exceptional item), which is comparable to the profit of Rs 279 million reported in the same quarter last year 9MFY24 (Apr-Dec) Revenue: Rs 13,268 million (9.6% increase from Rs 12,101 million in the same period last year) EBIDTA: Rs 2,006 million, 15.1% of net sales (against Rs 2,207 million, 18.2% of net sales in the previous year) Profit After Tax: Rs 873 million (before exceptional item), 6.6% of net sales (compared to 9.6% or Rs 1,160 million in the same period last year) Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated: "Our Q3 performance is primarily driven by International business particularly US and Emerging Markets, API business and steady performance by India business." Result PDF
23-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Appointment of Mr. Ajay Mulgaonkar and Mr. Satish Shenoy as a Additional Independent Director of the Company for a term of 5 years w.e.f. 01st April, 2024 to 31st March, 2029 subject to the approval of shareholders
23-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2023

 Approval of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2023
23-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 23Rd January, 2024

 we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd January, 2024 has inter-alia considered and approved the following. 1. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. 2. Appointment of Mr. Ajay Mulgaokar (DIN: 10457626) as an Additional Director and Non-Executive Independent Director on the Board of the Company to hold office for a term of five (5) years from 01st April, 2024 to 31st March, 2029, subject to approval of the shareholders. 3. Appointment of Mr. Satish Shenoy (DIN: 00230711) as an Additional Director and Non-Executive Independent Director on the Board of the Company to hold office for a term of five (5) years from 01st April, 2024 to 31st March, 2029, subject to approval of the shareholders.
23-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 RECEIPT OF ESTABLISHMENT INSPECTION REPORT BY INDOCO REMEDIES LIMITED-CLOSURE OF USFDA INSPECTION OF GOA PLANT -I
18-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Earnings Conference Call on unaudited financial results for quarter and nine months ended 31st December, 2023
17-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended 31St December, 2023.

 INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 23rd January, 2024, inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31st December, 2023.
10-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate issued by Registrar and Transfer Agent of the Company, confirming compliance under Reg 74(5) of SEBI (DP)Regulations,2018 for the quarter ended 31-12-2023
08-01-2024
Bigul

INDOCO REMEDIES LTD. - 532612 - Closure of Trading Window

 Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 this is to inform you that Trading Window for trading/dealing in Equity Shares of the Company will remain closed from 01st January, 2024 until 48 hours after declaration of Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2023
28-12-2023
Next Page
Close

Let's Open Free Demat Account